© Springer International Publishing AG 2018 329
A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory
Bowel Disease with Biologics, https://doi.org/10.1007/978-3-319-60276-9
A
Abbreviated new drug application (aNDA),
262
Adalimumab, 17, 20–22, 34, 37–39
CD
clinical efficacy, 37, 38
fistula healing, 39
mucosal healing, 38, 39
treatment, pediatric IBD, 169–172
UC
induction and maintenance clinical
trials, 17, 20–22
lond term efficacy and safety data, 22
tolerence, 21
Additional Long-Term Dosing With HUMIRA
to Evaluate Sustained Remission
and Efficacy in CD (ADHERE), 38
AJM300 (Anti-α 4 Integrin), 288
Alicaforsen (ISIS 2302), 295, 296
AMG 181, 293
Anklylosing spondylitis (AS), 51
Annual tuberculosis screening, 323
ANSER assays, 119
Anti-adhesion therapies. See Anti-integrin
medications
Antibody to infliximab (ATI), 233
Anti-drug antibodies, 118, 119, 283
Anti-IL-12/IL-23 agents, 6, 92, 93
Anti-integrin medications, 5, 91, 92, 94, 95
adhesion molecules, mechanism of action,
284
breastfeeding
natalizumab, 94
safety, 95
ustekinumab, 95
vedolizumab, 94
clinical efficacy and safety, 290
pregnancy
natalizumab, 91, 92
vedolizumab, 92
Anti-tumor necrosis factor (anti-TNF) agents,
14, 15, 19, 26–28, 34, 38, 43, 134,
213, 214
adhesion molecules, 33
biologic therapy, 29
CD, 33, 37, 39
adalimumab (see Adalimumab)
biologic therapy, 134
certolizumab pegol (see Certolizumab
pegol)
Etanercept, 43
infliximab (see Infliximab)
in vitro mechanisms, drugs, 43
proximal stoma, 134
seminal clinical trials, 34, 38
serum drug concentration, 43
cost effective, 43
disease activity, 33
drug levels, 118
fibroblast proliferation, 33
granuloma formation in vitro, 33
immune suppression, 30
infectious and noninfectious complications,
132, 133
insurance authorization, 29
malignancy risks
complications, 213
safety and efficacy, 214
types, 214
on molecular processes, 2
molecular structure, 83
older patients, 24, 25